No Benefit With Rituximab Maintenance Following Complete Remission for Diffuse Large B-Cell Lymphoma
Patients receiving rituximab maintenance and undergoing observation demonstrated similar rates of overall and disease-free survival.
ASCO 2019
ASCO 2019
Prognostic Factors for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Geriatric Patients
Impaired ability to conduct instrumental activities of daily living and high disease risk index were associated with poorer outcomes.
Determining Optimal Consolidation for First-Line Peripheral T-Cell Lymphoma Therapy
Current guidelines support autologous transplantation for consolidation in transplant-eligible patients with peripheral T-cell lymphoma.
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Frontline Rituximab Plus Bendamustine in Waldenström Macroglobulinemia
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
Stem Cell Transplantation in Patients With Amyloidosis Involving 3 or More Organs Is Safe
No association was found between number of organs involved and progression-free or overall survival in patients with amyloidosis who underwent transplant.
Treatment With Daratumumab for Multiple Myeloma May Improve Quality of Life
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
Improved Outcomes With Daratumumab Induction and Consolidation in Transplant-Eligible Multiple Myeloma
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Induction Chemotherapy Intensity May Not Influence Survival in Acute Myeloid Leukemia
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Meta-Analysis of Progression-Free Survival in Phase 3 Trials of Follicular Lymphoma Treatments
In this meta-analysis, researchers analyzed progression-free survival outcomes for 11 treatment regimens in pairwise comparisons.
Daratumumab Improves Outcomes in Combination With Lenalidomide, Dexamethasone for Relapsed/Refractory Multiple Myeloma
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Once-Weekly Carfilzomib Is Tolerable in Patients With Relapsed/Refractory Multiple Myeloma
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Long-Term Outcomes of Ibrutinib in Chronic Lymphocytic Leukemia
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...